查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1413848

抗體治療市場：按劑型、給藥途徑、來源、疾病領域和最終用戶 - 2024-2030 年全球預測

Antibody Therapeutics Market by Format (Antibody Fragment, Bispecific Antibody, Monoclonal Antibody), Route of Administration (Intravenous, Subcutaneous), Source, Disease Areas, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年抗體治療市場規模為2,487.9億美元，2024年將達2,857.7億美元，2030年將達6,575億美元，複合年成長率為14.89%。

抗體治療的全球市場

主要市場統計
基準年[2023] 2487.9億美元
預測年份 [2024] 2857.7億美元
預測年份 [2030] 6575億美元
複合年成長率（%） 14.89%
抗體治療藥物市場-IMG1

抗體療法是一類使用抗體來模擬或增強免疫系統對抗疾病的能力的醫學治療方法。抗體療法的精確性使得客製化治療能夠提供比傳統藥物更高的特異性和更低的毒性，使其能夠有效治療多種疾病，包括癌症、自體免疫疾病和感染疾病。慢性病的增加和全球醫療成本的上升導致抗體療法的採用增加。然而，高昂的開發成本以及漫長而複雜的監管核准限制了抗體療法的普及。然而，醫療技術的進步提高了抗體的生產效率。此外，新一代抗體的出現以及政府對癌症治療和護理的支持措施預計將為抗體治療市場帶來潛在商機。

區域洞察

在美洲，抗體治療市場在完善的研發生態系統、廣泛的專利組合和高昂的醫療成本的支持下呈現強勁成長。此外，美洲是許多大型生物製藥公司的所在地，這些公司正在投入大量資源來開發單株抗體和新藥。在亞太地區，由於醫療基礎設施的改善和慢性病的增加，對抗體治療的需求正在迅速增加。此外，由於強大的研究機構和政府支持政策的支持，個人化醫療和抗體開發取得了進步，亞太地區的抗體治療市場正在成長。歐盟（EU）國家憑藉其強大的製藥工業、廣泛的研究措施和全面的智慧財產權框架，在抗體治療市場中佔據著舉足輕重的地位。此外，中東和非洲國家正在投資最先進的醫療設施和醫療創新。

FPNV定位矩陣

FPNV 定位矩陣對於評估抗體治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限。最前線 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對抗體治療市場供應商的現狀進行深入而深入的研究。透過仔細比較和分析供應商在整體收入、客戶群和其他關鍵指標方面的貢獻，讓企業更深入地了解供應商收益以及他們在爭奪市場佔有率時面臨的挑戰。此外，該分析也為該產業的競爭特徵提供了寶貴的見解，包括在研究基準年觀察到的累積、分散優勢和合併特徵等因素。這種擴展的詳細程度使供應商能夠做出更明智的決策並制定有效的策略來參與市場競爭。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2- 市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管核准、專利狀況和製造能力進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-抗體治療市場的市場規模和預測是多少？

2-抗體治療市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3-抗體治療市場的技術趨勢和法律規範是什麼？

4-抗體治療市場主要供應商的市場佔有率是多少？

5-進入抗體治療市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 各種癌症和感染疾病的發生率增加
      • 世界各地的藥物研發活動不斷增加
      • 政府促進獲得抗體治療和療法的舉措
    • 抑制因素
      • 抗體治療產品回想的發生率與嚴格的核准指引有關
    • 機會
      • 抗體療法的臨床開發進展
      • 新抗體療法和治療方法的核准仍在繼續
    • 任務
      • 各種治療方法效果不足及副作用
  • 市場區隔分析
    • 劑型：單株抗體的大量使用，並獲得眾多監管機構核准用於臨床
    • 給藥途徑：增加靜脈注射抗體治療的使用
    • 來源：由於生物相容性，人類抗體的使用增加
    • 疾病領域：感染疾病抗體療法的使用迅速增加
    • 最終用戶：醫院使用抗體療法的方式正在不斷發展
  • 市場趨勢分析
    • 抗體療法的先進研究和開發活動得到了政府資助和美洲全球知名製藥公司的合作努力的支持。
    • 慢性病和感染疾病負擔日益增加，亞太地區對抗體治療的需求不斷增加
    • 生技公司在歐洲、中東和非洲擴張，臨床試驗進展
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章 抗體治療藥物市場：按劑型

  • 介紹
  • 抗體片段
  • 雙特異性抗體
  • 單株抗體
  • 多克隆抗體

第7章 抗體治療藥物市場：依給藥途徑分類

  • 介紹
  • 靜脈
  • 皮下的

第8章抗體治療市場：依來源分類

  • 介紹
  • 嵌合體
  • 人類
  • 人性化

第9章抗體治療藥物市場：依疾病領域

  • 介紹
  • 自體免疫疾病與發炎疾病
  • 血液學
  • 免疫學
  • 神經病學
  • 腫瘤學
  • 骨學

第10章抗體治療市場：依最終用戶分類

  • 介紹
  • 醫院
  • 療養院

第11章美洲抗體治療藥物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太抗體治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲抗體治療藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析
    • 併購
    • 合約、合作和夥伴關係
    • 新產品發布和功能增強
    • 投資、資金籌措
    • 獎項/獎勵/擴展

第15章競爭組合

  • 主要公司簡介
    • AbbVie Inc.
    • AbCellera Biologics Inc.
    • Adaptimmune Therapeutics PLC
    • ADC Therapeutics SA
    • Aenova Holding GmbH
    • Almac Group Limited
    • Amgen Inc.
    • Antikor Biopharma
    • Argenx SE
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Baxter International Inc.
    • Bayer AG
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Biogen Inc.
    • BioNTech SE
    • Bristol-Myers Squibb Company
    • Confo Therapeutics
    • DH Life Sciences, LLC
    • DotBio Pte. Ltd.
    • Eli Lilly and Company
    • Emergent BioSolutions Inc.
    • Evonik Industries AG
    • F. Hoffmann-La Roche Ltd.
    • GE HealthCare Technologies, Inc.,
    • Genmab A/S
    • GlaxoSmithKline PLC
    • Grifols, SA
    • Incyte Corporation
    • iTeos Therapeutics, Inc.
    • Johnson & Johnson Services, Inc.
    • Merck KGaA
    • Merus NV
    • MoonLake Immunotherapeutics AG
    • MorphoSys AG
    • Novartis AG
    • Novo Nordisk A/S
    • Numab Therapeutics AG
    • Pfizer Inc.
    • PharmAbcine Inc.
    • Pyxis Oncology, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • SAB Biotherapeutics, Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Thermo Fisher Scientific Inc.
    • TRIO Pharmaceuticals Inc.
    • UCB SA
    • Xencor, Inc.
  • 主要產品系列

第16章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-A42893A596EA

[188 Pages Report] The Antibody Therapeutics Market size was estimated at USD 248.79 billion in 2023 and expected to reach USD 285.77 billion in 2024, at a CAGR 14.89% to reach USD 657.50 billion by 2030.

Global Antibody Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 248.79 billion
Estimated Year [2024] USD 285.77 billion
Forecast Year [2030] USD 657.50 billion
CAGR (%) 14.89%
Antibody Therapeutics Market - IMG1

Antibody therapeutics are a class of medical treatments that employ antibodies to mimic or enhance the immune system's ability to fight diseases. The precision of antibody therapeutics allows for tailored treatments that provide high specificity and lower toxicity profiles than conventional drugs, making them effective in treating various conditions, including cancers, autoimmune diseases, and infectious diseases. The increasing incidences of chronic diseases and increased healthcare expenditure globally have increased the adoption of antibody therapeutics. However, high costs associated with development and lengthy and complex regulatory approvals limit the penetration of antibody therapeutics. Nevertheless, advancements in medical technology are leading to more productive antibody production. In addition, the emergence of next-generation antibodies and supportive government initiatives for cancer care and treatments are expected to offer potential opportunities for the antibody therapeutics market.

Regional Insights

In the Americas, antibody therapeutics market exhibit robust growth supported by a well-established R&D ecosystem, extensive patent portfolio, and high healthcare expenditure. Furthermore, the Americas includes numerous biopharmaceutical giants, which dedicate substantial resources to developing monoclonal antibodies and novel drug discovery. The Asia-Pacific region experienced a surge in the need for antibody therapeutics due to a growing healthcare infrastructure and increased incidences of chronic disease. Moreover, the Asia-Pacific region is witnessing growth in the antibody therapeutics market owing to the advances in personalized medicine and antibody development, supported by its strong research institutions and supportive government policies. Given their strong pharmaceutical industry, extensive research initiatives, and comprehensive intellectual property rights framework, European Union countries are pivotal in the antibody therapeutics landscape. In addition, countries in the Middle East and Africa are investing in state-of-the-art medical facilities and healthcare innovation.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AbCellera Biologics Inc., Adaptimmune Therapeutics PLC, ADC Therapeutics SA, Aenova Holding GmbH, Almac Group Limited, Amgen Inc., Antikor Biopharma, Argenx SE, Astellas Pharma Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biogen Inc., BioNTech SE, Bristol-Myers Squibb Company, Confo Therapeutics, DH Life Sciences, LLC, DotBio Pte. Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., Evonik Industries AG, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc.,, Genmab A/S, GlaxoSmithKline PLC, Grifols, S.A., Incyte Corporation, iTeos Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Merus N.V., MoonLake Immunotherapeutics AG, MorphoSys AG, Novartis AG, Novo Nordisk A/S, Numab Therapeutics AG, Pfizer Inc., PharmAbcine Inc., Pyxis Oncology, Inc., Regeneron Pharmaceuticals, Inc., SAB Biotherapeutics, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., TRIO Pharmaceuticals Inc., UCB S.A., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Format
    • Antibody Fragment
    • Bispecific Antibody
    • Monoclonal Antibody
    • Polyclonal Antibody
  • Route of Administration
    • Intravenous
    • Subcutaneous
  • Source
    • Chimeric
    • Human
    • Humanized
  • Disease Areas
    • Autoimmune & Inflammatory Diseases
    • Hematology
    • Immunology
    • Neurology
    • Oncology
    • Osteology
  • End User
    • Hospitals
    • Long-term Care Facilities
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibody Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Antibody Therapeutics Market?

4. What is the market share of the leading vendors in the Antibody Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Antibody Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antibody Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of various cancers and infectious diseases
      • 5.1.1.2. Increasing number of drug discovery activities worldwide
      • 5.1.1.3. Government initiatives to promote access to antibody treatments and therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of product recalls of antibody therapeutics coupled with strict approval guidelines
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the clinical development of antibody therapeutics
      • 5.1.3.2. Ongoing approvals for novel antibody therapies and treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Insufficient efficacy and adverse effects associated with various treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Format: Significant utilization of monoclonal antibodies due to numerous approvals by regulatory agencies for clinical use
    • 5.2.2. Route of Administration: Growing usage of intravenous administration of antibody therapeutics
    • 5.2.3. Source: Increasing use of human antibodies due to its biocompatible nature
    • 5.2.4. Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
    • 5.2.5. End User: Evolving usage of antibody therapeutics in hospitals
  • 5.3. Market Trend Analysis
    • 5.3.1. Advanced R&D activities in antibody therapeutics backed by government funding and partnership activities by global established pharmaceutical companies in Americas
    • 5.3.2. Growing burden of chronic and infectious diseases creating need for antibody therapeutics in the Asia-Pacific
    • 5.3.3. Ongoing clinical trials coupled with expansion of biotech companies in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antibody Therapeutics Market, by Format

  • 6.1. Introduction
  • 6.2. Antibody Fragment
  • 6.3. Bispecific Antibody
  • 6.4. Monoclonal Antibody
  • 6.5. Polyclonal Antibody

7. Antibody Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Subcutaneous

8. Antibody Therapeutics Market, by Source

  • 8.1. Introduction
  • 8.2. Chimeric
  • 8.3. Human
  • 8.4. Humanized

9. Antibody Therapeutics Market, by Disease Areas

  • 9.1. Introduction
  • 9.2. Autoimmune & Inflammatory Diseases
  • 9.3. Hematology
  • 9.4. Immunology
  • 9.5. Neurology
  • 9.6. Oncology
  • 9.7. Osteology

10. Antibody Therapeutics Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals
  • 10.3. Long-term Care Facilities

11. Americas Antibody Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antibody Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antibody Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player
    • 14.3.1. Merger & Acquisition
      • 14.3.1.1. AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
      • 14.3.1.2. Pyxis Oncology to acquire Antibody Therapeutics Company Apexigen
      • 14.3.1.3. Merck to Develop mAb Through USD 10.8 Billion Acquisition
    • 14.3.2. Agreement, Collaboration, & Partnership
      • 14.3.2.1. SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
      • 14.3.2.2. AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
      • 14.3.2.3. Salipro Partners with Icosagen to Develop Monoclonal Antibody Therapies
      • 14.3.2.4. AbCellera, Incyte Partner on Therapeutic Antibodies in Oncology
      • 14.3.2.5. Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
    • 14.3.3. New Product Launch & Enhancement
      • 14.3.3.1. U.S. FDA Approves TALVEY, a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
    • 14.3.4. Investment & Funding
      • 14.3.4.1. MBrace Therapeutics Raises USD 85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates
      • 14.3.4.2. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
      • 14.3.4.3. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
    • 14.3.5. Award, Recognition, & Expansion
      • 14.3.5.1. Japan Grants Patent for Bioarctic's Parkinson's Disease Antibody

15. Competitive Portfolio

  • 15.1. Key Company Profiles
    • 15.1.1. AbbVie Inc.
    • 15.1.2. AbCellera Biologics Inc.
    • 15.1.3. Adaptimmune Therapeutics PLC
    • 15.1.4. ADC Therapeutics SA
    • 15.1.5. Aenova Holding GmbH
    • 15.1.6. Almac Group Limited
    • 15.1.7. Amgen Inc.
    • 15.1.8. Antikor Biopharma
    • 15.1.9. Argenx SE
    • 15.1.10. Astellas Pharma Inc.
    • 15.1.11. AstraZeneca PLC
    • 15.1.12. Baxter International Inc.
    • 15.1.13. Bayer AG
    • 15.1.14. Becton, Dickinson and Company
    • 15.1.15. Bio-Rad Laboratories, Inc.
    • 15.1.16. Biogen Inc.
    • 15.1.17. BioNTech SE
    • 15.1.18. Bristol-Myers Squibb Company
    • 15.1.19. Confo Therapeutics
    • 15.1.20. DH Life Sciences, LLC
    • 15.1.21. DotBio Pte. Ltd.
    • 15.1.22. Eli Lilly and Company
    • 15.1.23. Emergent BioSolutions Inc.
    • 15.1.24. Evonik Industries AG
    • 15.1.25. F. Hoffmann-La Roche Ltd.
    • 15.1.26. GE HealthCare Technologies, Inc.,
    • 15.1.27. Genmab A/S
    • 15.1.28. GlaxoSmithKline PLC
    • 15.1.29. Grifols, S.A.
    • 15.1.30. Incyte Corporation
    • 15.1.31. iTeos Therapeutics, Inc.
    • 15.1.32. Johnson & Johnson Services, Inc.
    • 15.1.33. Merck KGaA
    • 15.1.34. Merus N.V.
    • 15.1.35. MoonLake Immunotherapeutics AG
    • 15.1.36. MorphoSys AG
    • 15.1.37. Novartis AG
    • 15.1.38. Novo Nordisk A/S
    • 15.1.39. Numab Therapeutics AG
    • 15.1.40. Pfizer Inc.
    • 15.1.41. PharmAbcine Inc.
    • 15.1.42. Pyxis Oncology, Inc.
    • 15.1.43. Regeneron Pharmaceuticals, Inc.
    • 15.1.44. SAB Biotherapeutics, Inc.
    • 15.1.45. Sanofi S.A.
    • 15.1.46. Takeda Pharmaceutical Company Limited
    • 15.1.47. Thermo Fisher Scientific Inc.
    • 15.1.48. TRIO Pharmaceuticals Inc.
    • 15.1.49. UCB S.A.
    • 15.1.50. Xencor, Inc.
  • 15.2. Key Product Portfolio

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIBODY THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2023 VS 2030 (%)
  • FIGURE 8. ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 12. ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2023 VS 2030 (%)
  • FIGURE 14. ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 26. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 18. ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. ANTIBODY THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 237. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. ANTIBODY THERAPEUTICS MARKET LICENSE & PRICING